

David J Kuter

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6154527/david-j-kuter-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

6,606
citations

35
h-index

80
g-index

190
ext. papers

8,078
ext. citations

4.9
avg, IF

6.51
L-index

#	Paper	IF	Citations
164	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. <i>Lancet, The</i> , 2008 , 371, 395-403	4.0	663
163	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. <i>Blood</i> , 2020 , 136, 489-500	2.2	642
162	Thrombocytopenia caused by the development of antibodies to thrombopoietin. <i>Blood</i> , 2001 , 98, 3241-8.	2.2	567
161	Romiplostim or standard of care in patients with immune thrombocytopenia. <i>New England Journal of Medicine</i> , 2010 , 363, 1889-99	59.2	313
160	Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. <i>Blood</i> , 2002 , 100, 3457-69	2.2	301
159	American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Advances</i> , 2019 , 3, 3829-3866	7.8	299
158	New thrombopoietic growth factors. <i>Blood</i> , 2007 , 109, 4607-16	2.2	272
157	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019 , 3, 3780-3817	7.8	267
156	Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. <i>British Journal of Haematology</i> , 2007 , 139, 351-62	4.5	192
155	Thrombotic complications of central venous catheters in cancer patients. <i>Oncologist</i> , 2004 , 9, 207-16	5.7	183
154	Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. <i>British Journal of Haematology</i> , 2013 , 161, 411-23	4.5	180
153	Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. <i>Blood</i> , 2009 , 114, 3748-56	2.2	152
152	Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. <i>Annual Review of Medicine</i> , 2009 , 60, 193-206	17.4	149
151	The biology of thrombopoietin and thrombopoietin receptor agonists. <i>International Journal of Hematology</i> , 2013 , 98, 10-23	2.3	142
150	The mechanism of apoptosis in human platelets during storage. <i>Transfusion</i> , 2000 , 40, 1320-9	2.9	138
149	Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. <i>British Journal of Haematology</i> , 1999 , 106, 345-56	4.5	127
148	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. <i>Blood Reviews</i> , 2020 , 41, 100648	11.1	109

147	The physiology of platelet production. <i>Stem Cells</i> , 1996 , 14 Suppl 1, 88-101	5.8	98
146	Biology and chemistry of thrombopoietic agents. <i>Seminars in Hematology</i> , 2010 , 47, 243-8	4	83
145	Thrombopoietin therapy increases platelet yields in healthy platelet donors. <i>Blood</i> , 2001 , 98, 1339-45	2.2	81
144	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. <i>Blood</i> , 2014 , 123, 3887-94	2.2	78
143	Milestones in understanding platelet production: a historical overview. <i>British Journal of Haematology</i> , 2014 , 165, 248-58	4.5	72
142	Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. <i>Haematologica</i> , 2018 , 103, 1433-1443	6.6	70
141	Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. <i>American Journal of Hematology</i> , 2012 , 87, 558-61	7.1	52
140	Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. <i>Blood Cells, Molecules, and Diseases</i> , 2013 , 51, 116-24	2.1	51
139	Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. <i>American Journal of Hematology</i> , 2013 , 88, 1041-4	7.1	45
138	Thrombopoietin and platelet production in chronic immune thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2009 , 23, 1193-211	3.1	45
137	Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. <i>American Journal of Hematology</i> , 2020 , 95, 178-187	7.1	45
136	The end is just the beginning: megakaryocyte apoptosis and platelet release. <i>International Journal of Hematology</i> , 2001 , 74, 365-74	2.3	44
135	Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. <i>International Journal of Hematology</i> , 2015 , 101, 255-63	2.3	40
134	Cancer, Coagulation, and Anticoagulation. <i>Oncologist</i> , 1999 , 4, 443-449	5.7	40
133	The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. <i>Haematologica</i> , 2018 , 103, e169-e172	6.6	37
132	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2019 , 10, 2040620719841735	5.7	36
131	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2019 , 94, 149-161	7.1	35
130	Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. <i>American Journal of Hematology</i> , 2018 , 93, 1501-1508	7.1	35

129	Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. <i>British Journal of Haematology</i> , 2019 , 185, 503-513	4.5	33
128	New thrombopoietic growth factors. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9 Suppl 3, S347-56		33
127	New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. <i>European Journal of Haematology</i> , 2008 , 80, 9-18	3.8	33
126	Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2017 , 92, 730-738	7.1	32
125	Apheresis platelets: emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. <i>Journal of Clinical Apheresis</i> , 1998 , 13, 114-9	3.2	29
124	Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).. <i>Blood</i> , 2004 , 104, 336-336	2.2	28
123	Thrombopoietin: Biology and Clinical Applications. <i>Oncologist</i> , 1996 , 1, 98-106	5.7	28
122	Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. <i>Molecular Genetics and Metabolism</i> , 2017 , 122, 122-129	3.7	27
121	Exacerbation of immune thrombocytopenia following COVID-19 vaccination. <i>British Journal of Haematology</i> , 2021 , 195, 365-370	4.5	27
120	Romiplostim for the management of perioperative thrombocytopenia. <i>British Journal of Haematology</i> , 2018 , 182, 106-113	4.5	27
119	An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the INHIBIT-Bleed study. <i>Haematologica</i> , 2021 , 106, 2161-2169	6.6	26
118	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. <i>Blood Advances</i> , 2020 , 4, 9-18	7.8	26
117	Hepatocellular carcinoma in Gaucher disease: an international case series. <i>Journal of Inherited Metabolic Disease</i> , 2018 , 41, 819-827	5.4	24
116	Romiplostim. <i>Cancer Treatment and Research</i> , 2011 , 157, 267-88	3.5	24
115	Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 275-288	5.3	23
114	A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. <i>Haematologica</i> , 2021 , 106, 1148-1157	6.6	23
113	Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. <i>Annals of Hematology</i> , 2019 , 98, 581-588	3	22
112	Romiplostim in the management of the thrombocytopenic surgical patient. <i>Transfusion</i> , 2015 , 55, 2505-109		20

111	Apoptosis in platelets during ex vivo storage. <i>Vox Sanguinis</i> , 2002 , 83 Suppl 1, 311-3	3.1	19
110	Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative. <i>Internal Medicine Journal</i> , 2019 , 49, 578-591	1.6	19
109	The use of PEG-rhuMGDF in platelet apheresis. <i>Stem Cells</i> , 1998 , 16 Suppl 2, 231-42	5.8	18
108	Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. <i>British Journal of Haematology</i> , 2018 , 183, 168	4.5	17
107	Remissions after long-term use of romiplostim for immune thrombocytopenia. <i>Haematologica</i> , 2016 , 101, e476-e478	6.6	16
106	An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2673-2677	3.8	15
105	Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2006 , 108, 3982-3982	2.2	15
104	Fondaparinux in the Treatment of Heparin-Induced Thrombocytopenia.. <i>Blood</i> , 2004 , 104, 1775-1775	2.2	14
103	Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19). <i>American Journal of Hematology</i> , 2020 , 95, 1479-1485	7.1	13
102	Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. <i>American Journal of Hematology</i> , 2020 , 95, 1180	7.1	12
101	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia. <i>Blood</i> , 2019 , 134, 87-87	2.2	11
100	What is the potential for thrombopoietic agents in acute leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 553-8	4.2	10
99	Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. <i>Blood Advances</i> , 2019 , 3, 3515-3521	7.8	10
98	Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. <i>British Journal of Haematology</i> , 2018 , 183, 466-478	4.5	10
97	SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients. <i>Blood</i> , 2021 ,	2.2	10
96	Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. <i>American Journal of Hematology</i> , 2020 , 95, 643-651 ¹	7.1	9
95	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. <i>Leukemia Research</i> , 2020 , 98, 106459	2.7	9
94	The role of romiplostim for pediatric patients with immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2020 , 11, 2040620720912992	5.7	8

93	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study. <i>Blood</i> , 2019 , 134, LBA-2-LBA-2	2.2	8
92	Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study. <i>Blood</i> , 2010 , 116, 68-68	2.2	8
91	Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia. <i>Blood</i> , 2020 , 136, 14-15	2.2	7
90	Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study. <i>Blood</i> , 2008 , 112, 402-402	2.2	7
89	An evaluation of avatrombopag for the treatment of thrombocytopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 273-280	4	7
88	Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma: A case report. <i>Medicine (United States)</i> , 2018 , 97, e13321	1.8	7
87	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 579-584.e1	2	6
86	TPO concentrations and response to romiplostim. <i>American Journal of Hematology</i> , 2014 , 89, 1155-6	7.1	6
85	Recurrence of Acute Intermittent Porphyria After Liver Transplantation. <i>Annals of Internal Medicine</i> , 2019 , 170, 904-905	8	6
84	Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. <i>Haematologica</i> , 2018 , 103, e492-e495	6.6	6
83	Safety and Efficacy of PRTX-100, a Highly Purified Form of Staphylococcal Protein A, in Patients with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2016 , 128, 4929-4929	2.2	5
82	What is the role of novel thrombopoietic agents in the management of acute leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 372-378	4.2	5
81	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 219-225	2	5
80	Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. <i>British Journal of Haematology</i> , 2020 , 190, 923-932	4.5	4
79	Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study. <i>Blood</i> , 2018 , 132, 3612-3612	2.2	4
78	Antiplatelet Antibody Testing in Immune Thrombocytopenia and Evans Syndrome: Longitudinal Serologic Evolution and Relation to Clinical Features. <i>Blood</i> , 2018 , 132, 1137-1137	2.2	4
77	Inhibition of the Classical Pathway of Complement with Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients without Adequate Response to Two or More Prior Therapies. <i>Blood</i> , 2019 , 134, 898-898	2.2	4
76	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019 , 134, 4172-4172	2.2	4

75	Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study. <i>Blood</i> , 2020 , 136, 1-3	2.2	4
74	A Randomized, Double-Blind, Placebo-Controlled Phase II Trial on the Efficacy, Safety and Tolerability of E5501 (AKR501) In Subjects with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2010 , 116, 71-71	2.2	4
73	Thrombopoietin Levels May Predict Responsiveness to Therapy with Thrombopoietin Agonists Among Patients with Immune Thrombocytopenic Purpura,. <i>Blood</i> , 2011 , 118, 3288-3288	2.2	4
72	Novel therapies for immune thrombocytopenia. <i>British Journal of Haematology</i> , 2021 ,	4.5	4
71	Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. <i>Liver International</i> , 2021 ,	7.9	4
70	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2020 , 13, 1319-1332	2.8	4
69	How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. <i>Blood</i> , 2021 , 137, 2736-2744	2.2	4
68	General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors 2019 , 108-126		4
67	Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. <i>Blood Reviews</i> , 2021 , 49, 100811	11.1	4
66	Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.. <i>American Journal of Hematology</i> , 2022 ,	7.1	4
65	Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. <i>British Journal of Haematology</i> , 2019 , 187, e61-e64	4.5	3
64	Assessment of Romiplostim Immunogenicity in Adult Patients in Clinical Trials and in a Global Registry. <i>Blood</i> , 2018 , 132, 2427-2427	2.2	3
63	Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia. <i>Blood</i> , 2020 , 136, 13-14	2.2	3
62	Analysis of Mortality Rates During Romiplostim Clinical Studies of Patients (Pts) with Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2010 , 116, 3701-3701	2.2	3
61	The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. <i>Blood Reviews</i> , 2021 , 100909	11.1	3
60	Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose 1998 , 13, 114		3
59	In Reply: Low-Dose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients. Can It Be Safely Associated with 5-Fluorouracil-Based Chemotherapy?. <i>Oncologist</i> , 2004 , 9, 596-596	5.7	2
58	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up. <i>Blood</i> , 2020 , 136, 24-25	2.2	2

57	A Comparative Proteomic Analysis of Platelets from Healthy Human Patients and Chronic ITP Patients Receiving AMG 531, a Thrombopoiesis-Stimulating Protein.. <i>Blood</i> , 2007 , 110, 1313-1313	2.2	2
56	Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.. <i>Blood</i> , 2009 , 114, 679-679	2.2	2
55	Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.. <i>Blood</i> , 2009 , 114, 681-681	2.2	2
54	Efficacy, Safety and Tolerability of E5501 (AKR501) In a 6-Month Extension Study In Subjects with Chronic Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2010 , 116, 3695-3695	2.2	2
53	Romiplostim for Treatment and Prevention of Chemotherapy-Associated Thrombocytopenia. <i>Blood</i> , 2016 , 128, 3748-3748	2.2	2
52	Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilizabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 14-14	2.2	2
51	LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilizabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 1010-1010	2.2	2
50	Scoring system to facilitate diagnosis of Gaucher disease. <i>Internal Medicine Journal</i> , 2020 , 50, 1538-1546	1.6	2
49	Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1178-1180	4.4	2
48	Rilizabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.. <i>New England Journal of Medicine</i> , 2022 , 386, 1421-1431	59.2	2
47	Case 38-2020: A 52-Year-Old Man with Cancer and Acute Hypoxemia. <i>New England Journal of Medicine</i> , 2020 , 383, 2372-2383	59.2	1
46	Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: a case report. <i>BMC Pregnancy and Childbirth</i> , 2020 , 20, 365	3.2	1
45	The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. <i>British Journal of Haematology</i> , 2000 , 111, 943-953	4.5	1
44	Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database. <i>Blood</i> , 2018 , 132, 3284-3284	2.2	1
43	Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study. <i>Blood</i> , 2019 , 134, 3518-3518	2.2	1
42	Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension. <i>Blood</i> , 2020 , 136, 13-13	2.2	1
41	The Incidence of Thrombosis in Patients with Isolated Heparin Induced Thrombocytopenia.. <i>Blood</i> , 2006 , 108, 1049-1049	2.2	1
40	The Identification of Hypercoagulable Markers in Patients with Malignant Gliomas and Venous Thromboembolism.. <i>Blood</i> , 2006 , 108, 4097-4097	2.2	1

39	Patient Quality of Life (QOL) In Nonsplenectomized Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim or Medical Standard of Care (SOC). <i>Blood</i> , 2010 , 116, 569-569	2.2	1
38	An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival. <i>Blood</i> , 2015 , 126, 2093-2093	2.2	1
37	Markers of Autoimmunity in Immune Thrombocytopenia: Prevalence and Prognostic Significance. <i>Blood</i> , 2016 , 128, 1363-1363	2.2	1
36	Key Presenting Signs and Patient Co-Variables in Early Diagnosis of Type 3 Gaucher Disease: A Global Delphi Consensus Initiative. <i>Blood</i> , 2016 , 128, 4886-4886	2.2	1
35	Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6621-6621	2.2	1
34	Preparing patients with immune thrombocytopenia for surgery: what are the options?. <i>Lancet Haematology</i> , 2020 , 7, e626-e627	14.6	1
33	Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria. <i>American Journal of Hematology</i> , 2021 , 96, E235-E237	7.1	1
32	Pure White Cell Aplasia and Necrotizing Myositis. <i>Case Reports in Hematology</i> , 2016 , 2016, 4161679	0.7	1
31	Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00118	4.2	0
30	Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials. <i>Blood</i> , 2018 , 132, 3740-3740	2.2	0
29	Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia. <i>Blood</i> , 2019 , 134, 895-895	2.2	0
28	Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). <i>Blood</i> , 2021 , 138, 2088-2088	2.2	0
27	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 586-586	2.2	0
26	Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2020 , 82, 102418	2.1	0
25	Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2021 , 96, 1563-1568	7.1	0
24	Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease. <i>International Journal of Laboratory Hematology</i> , 2019 , 41, 325-330	2.5	0
23	Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress. <i>Blood</i> , 2020 , 136, 6-7	2.2	0
22	Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations. <i>Blood</i> , 2020 , 136, 29-29	2.2	0

21	Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19. <i>Blood</i> , 2020 , 136, 4-5	2.2
20	Long-Term Follow-Up of Monoclonal Gammopathies in Gaucher Disease Patients on Enzyme Replacement Therapy.. <i>Blood</i> , 2006 , 108, 3336-3336	2.2
19	Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study. <i>Blood</i> , 2018 , 132, 3285-3285	2.2
18	Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy. <i>Blood</i> , 2018 , 132, 3755-3755	2.2
17	Systemic Bevacizumab for the Treatment of Chronic Bleeding in Hereditary Hemorrhagic Telangiectasia. <i>Blood</i> , 2018 , 132, 852-852	2.2
16	Thrombopoietin Level Predicts Response to Treatment with Eltrombopag and Romiplostim in Immune Thrombocytopenia. <i>Blood</i> , 2018 , 132, 734-734	2.2
15	An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bleed Study. <i>Blood</i> , 2019 , 134, 1060-1060	2.2
14	Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia. <i>Blood</i> , 2019 , 134, 4800-4800	2.2
13	Romiplostim in Management of the Thrombocytopenic Surgical Patient. <i>Blood</i> , 2014 , 124, 1459-1459	2.2
12	A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Key Presenting Signs and Patient Co-Variables in Type 1 Disease. <i>Blood</i> , 2016 , 128, 3676-3676	2.2
11	A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Barriers, Their Resolution and the Impact on Patients. <i>Blood</i> , 2016 , 128, 4885-4885	2.2
10	An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy. <i>Blood</i> , 2016 , 128, 2403-2403	2.2
9	FF-10102-01: A Novel, Highly Selective Spleen Tyrosine Kinase Inhibitor, to Be in Clinical Application for Treatment of Autoimmune Diseases and B-Cell Malignancies. <i>Blood</i> , 2016 , 128, 3745-3745	2.2
8	Gestational Platelet Trends and Outcomes in Women with Myeloproliferative Disorders Characterized by Thrombocytosis. <i>Blood</i> , 2008 , 112, 5251-5251	2.2
7	The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.. <i>Blood</i> , 2010 , 116, 3702-3702	2.2
6	Thrombin Generation During Abdominal Surgical Procedures: Effect of Prophylactic Anticoagulation Therapy. <i>Blood</i> , 2010 , 116, 3183-3183	2.2
5	Patient Reported Outcomes Comparison of Chronic Immune Thrombocytopenia (ITP) Patients Switched to Promacta and Nplate. <i>Blood</i> , 2011 , 118, 2220-2220	2.2
4	Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study,. <i>Blood</i> , 2011 , 118, 3207-3207	2.2

- 3 A Double-Blind, Placebo-Controlled, and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ono-7746 in Healthy Subjects. *Blood*, **2011**, 118, 4828-4828 2.2
- 2 Single Oral Doses of a Novel Thrombopoietin Mimetic ONO-7746 Increase Platelet Counts In Healthy Subjects. *Blood*, **2011**, 118, 4827-4827 2.2
- 1 Lessons Learned Using Real-World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 1570-1578 6.1